A significant number of women under 50 who are at risk of breast cancer are not being included in current screening protocols, missing out on crucial preventive measures. Typically, women over 50 are routinely offered mammogram checks for cancer detection. However, the existing guidelines, as outlined by the National Institute of Health and Care Excellence (NICE), primarily focus on genetic factors and fail to consider other crucial aspects like lifestyle. Consequently, women under 50 are often overlooked for breast cancer screenings unless they have a strong family history of the disease.
A new risk assessment tool, Boadicea, developed by Cambridge and supported by Cancer Research UK, takes into account various factors such as family history, lifestyle choices, reproductive history, and genetic data. This innovative system has proven to identify eight times more at-risk women under 50 compared to the current screening guidelines.
The current NICE criteria, used to determine referrals for further breast cancer risk assessment and specialized care, are falling short in identifying a significant portion of women under 50 who are likely to develop breast cancer within the next decade. This inadequacy has led to calls for a review of the existing criteria to ensure a more inclusive approach to screening younger women for breast cancer.
Breast cancer remains one of the most prevalent types of cancer globally, constituting approximately a quarter of all cancer cases and being a leading cause of death among women under 50 in the UK. Despite this, only a small percentage of cases are linked to inherited genes, with a majority of women under 50 who develop breast cancer having no family history of the disease.
Research suggests that the criteria provided to general practitioners in England miss up to 95% of women under 50 who could potentially develop breast cancer within ten years, as well as 95% of younger women with an above-average risk. Detecting individuals at higher risk early on could significantly improve the chances of successful treatment or even prevention of breast cancer.
Dr. Juliet Usher-Smith from the University of Cambridge emphasizes the need for better identification of women at the highest risk of breast cancer to facilitate early intervention, thereby enhancing treatment options and potential prevention strategies. The current NICE criteria are highlighted for their shortcomings in capturing a significant portion of women under 50 at risk of developing breast cancer, calling for a reevaluation based on the latest findings.
Professor Montserrat García-Closas from the ICR acknowledges the challenge of balancing the practicality and resource implications of implementing comprehensive risk assessments, including genetic testing, against the benefits and potential drawbacks associated with accurately identifying women at elevated risk of breast cancer.
Dr. Simon Vincent, chief scientific officer at Breast Cancer Now, underscores the limitations of the current NICE referral criteria and stresses the importance of incorporating the latest research into the ongoing review of family history guidelines. Any proposed changes must be accompanied by sufficient investment in family history services to ensure effective and equitable implementation across the NHS.
NICE has acknowledged the findings of the study, recognizing the potential of multifactorial risk models in enhancing the identification of women at increased risk of breast cancer in the future. While the current evidence does not warrant an immediate change to the existing familial breast cancer guideline, NICE remains committed to evaluating new data and considering updates as more information on feasibility and clinical outcomes becomes available.